MiR‐146a Deletion Protects From Bone Loss in OVX Mice by Suppressing RANKL/OPG and M‐CSF in Bone Microenvironment
暂无分享,去创建一个
Xiaoling Zhang | G. Hu | Xiaoying Zhao | Xudong Zhang | Penglei Cui | Jiajia Xu | Jingyu Zhao | M. Huang
[1] N. Troiano,et al. Selective deletion of the soluble Colony-Stimulating Factor 1 isoform in vivo prevents estrogen-deficiency bone loss in mice , 2017, Bone Research.
[2] U. Urzúa,et al. Parity History Determines a Systemic Inflammatory Response to Spread of Ovarian Cancer in Naturally Aged Mice , 2017, Aging and disease.
[3] J. Inoue,et al. miR-146a–Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression , 2017, Proceedings of the National Academy of Sciences.
[4] Chuandong Wang,et al. miR-146a facilitates osteoarthritis by regulating cartilage homeostasis via targeting Camk2d and Ppp3r2 , 2017, Cell Death & Disease.
[5] F. Slack,et al. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.
[6] Xianqun Fan,et al. Effects of miR-146a on the osteogenesis of adipose-derived mesenchymal stem cells and bone regeneration , 2017, Scientific Reports.
[7] Y. Fujiwara,et al. RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice* , 2016, The Journal of Biological Chemistry.
[8] C. Cooper,et al. Novel advances in the treatment of osteoporosis. , 2016, British medical bulletin.
[9] Xiaoling Zhang,et al. IL-12p40 impairs mesenchymal stem cell-mediated bone regeneration via CD4+ T cells , 2016, Cell Death and Differentiation.
[10] V. Leung,et al. The Regulatory Roles of MicroRNAs in Bone Remodeling and Perspectives as Biomarkers in Osteoporosis , 2016, BioMed research international.
[11] Xijie Yu,et al. MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis , 2016, International journal of molecular sciences.
[12] P. Andreopoulou,et al. Management of postmenopausal osteoporosis. , 2015, Annual review of medicine.
[13] C. Franceschi,et al. Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy – A study with monozygotic twin pairs , 2014, Mechanisms of Ageing and Development.
[14] S. Booth,et al. MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response , 2014, Front. Immunol..
[15] W. Ge,et al. The role of MicroRNAs in Osteoclasts and Osteoporosis , 2014, RNA biology.
[16] A. Schulz,et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function , 2013, Nature Reviews Endocrinology.
[17] C. Jorgensen,et al. Impact of microRNAs on the understanding and treatment of rheumatoid arthritis , 2013, Current opinion in rheumatology.
[18] E. Ambrogini,et al. Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. , 2013, The Journal of clinical investigation.
[19] E. Chan,et al. MicroRNA-146a in autoimmunity and innate immune responses , 2012, Annals of the rheumatic diseases.
[20] Xiaogang Wang,et al. miR-214 targets ATF4 to inhibit bone formation , 2012, Nature Medicine.
[21] S. Khosla,et al. Estrogen and the skeleton , 2012, Trends in Endocrinology & Metabolism.
[22] C. Klinge. miRNAs and estrogen action , 2012, Trends in Endocrinology & Metabolism.
[23] U. Testa,et al. The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer , 2012, Journal of Hematology & Oncology.
[24] M. Satoh,et al. MicroRNAs in rheumatoid arthritis , 2011, FEBS letters.
[25] M. Ochi,et al. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. , 2011, Arthritis and rheumatism.
[26] P. Linsley,et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice , 2011, The Journal of experimental medicine.
[27] Ryan M. O’Connell,et al. NF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies , 2011, Proceedings of the National Academy of Sciences.
[28] T. Rachner,et al. Osteoporosis: now and the future , 2011, The Lancet.
[29] H. Worch,et al. Development of an osteoblast/osteoclast co-culture derived by human bone marrow stromal cells and human monocytes for biomaterials testing. , 2011, European cells & materials.
[30] Huiqing Yuan,et al. MicroRNAs and prostate cancer. , 2010, Acta biochimica et biophysica Sinica.
[31] P. Roberson,et al. Estrogens Attenuate Oxidative Stress and the Differentiation and Apoptosis of Osteoblasts by DNA-Binding-Independent Actions of the ERα , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] F. Geissmann,et al. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. , 2009, Annual review of immunology.
[33] O. Crasta,et al. Suppression of LPS-induced Interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. , 2008, Blood.
[34] Keiichiro Nishida,et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. , 2008, Arthritis and rheumatism.
[35] M. Almeida,et al. Induction of Osteoblast Differentiation by Selective Activation of Kinase-Mediated Actions of the Estrogen Receptor , 2006, Molecular and Cellular Biology.
[36] D. Black,et al. Clinical Practice. Postmenopausal Osteoporosis. , 2005, The New England journal of medicine.
[37] Kwan Tat Steeve,et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .
[38] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[39] R. Pacifici. Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis-The Second Decade. , 1998, Endocrinology.
[40] R. Jilka,et al. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. , 1995, The New England journal of medicine.
[41] P. Marie,et al. Increased proliferation of osteoblast precursor cells in estrogen-deficient rats. , 1993, The American journal of physiology.
[42] D. Kalu. The ovariectomized rat model of postmenopausal bone loss. , 1991, Bone and mineral.
[43] F. Claessens,et al. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. , 2017, Physiological reviews.
[44] John D Lambris,et al. Does complement play a role in bone development and regeneration? , 2013, Immunobiology.
[45] R. Baron,et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. , 2002, Bone.
[46] R. Pacifici. Cytokines, estrogen, and postmenopausal osteoporosis--the second decade. , 1998, Endocrinology.
[47] J. Lehoux,et al. On the presence of nonfunctional uterine estrogen receptors in middle-aged and old C57BL/6J mice. , 1985, Endocrinology.